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Abstract
Objective. Timely access to holistic multidisciplinary care is the core principle underpinning management
of juvenile idiopathic arthritis (JIA). Data collected in national clinical audit programmes fundamentally aim
to improve health outcomes of disease, ensuring clinical care is equitable, safe and patient-centred. The
aim of this study was to develop a tool for national audit of JIA in the UK.
Methods. A staged and consultative methodology was used across a broad group of relevant stake-
holders to develop a national audit tool, with reference to pre-existing standards of care for JIA. The tool
comprises key service delivery quality measures assessed against two aspects of impact, namely dis-
ease-related outcome measures and patient/carer reported outcome and experience measures.
Results. Eleven service-related quality measures were identified, including those that map to current
standards for commissioning of JIA clinical services in the UK. The three-variable Juvenile Arthritis
Disease Activity Score and presence/absence of sacro-iliitis in patients with enthesitis-related arthritis
were identified as the primary disease-related outcome measures, with presence/absence of uveitis a
secondary outcome. Novel patient/carer reported outcomes and patient/carer reported experience meas-
ures were developed and face validity confirmed by relevant patient/carer groups.
Conclusion. A tool for national audit of JIA has been developed with the aim of benchmarking current
clinical practice and setting future standards and targets for improvement. Staged implementation of this
national audit tool should facilitate investigation of variability in levels of care and drive quality improve-
ment. This will require engagement from patients and carers, clinical teams and commissioners of JIA
services.
Key words: Juvenile idiopathic arthritis, outcomes, audit, patient reported outcome measure, patient reported
experience measure, standards of care, quality
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Rheumatology key messages
. We report development of a national clinical audit tool for children with JIA.
. Staged implementation of national audit will inform future quality improvement interventions in JIA.
. We propose future development of an electronic data collection tool integrated into electronic patient records.
Introduction
JIA is an umbrella term for a heterogeneous group of con-
ditions characterized by chronic arthritis and categorized
into sub-types according to clinical features at onset
[1, 2]. JIA is one of the most common chronic inflamma-
tory diseases of childhood with a UK incidence of 1:10 000
reported by Symmons et al. [3] in 1996. Although this
equates to at least 1000 new cases per annum in the
UK, the figure is almost certainly an underestimate; at
that time, it was only possible to identify incident cases
presenting to specialist paediatric centres. More recent
incident data from other countries are higher [4, 5].
Appropriately tailored interventions are central to
minimizing the adverse impact of JIA on physical, psycho-
logical and visual function, health-related quality of life
and social/educational attainments [6]. However, there is
wide variation in severity of presentation and disease
course, and treatment-related morbidity can be signifi-
cant. In part as a consequence of this heterogeneity,
high quality evidence supporting best practice in JIA is
limited, resulting in wide variations in service delivery.
The British Society for Paediatric and Adolescent
Rheumatology (BSPAR)/Arthritis and Musculoskeletal
Alliance Standards of Care (SOC) for Children and
Young People (CYP) with JIA (2009) are consensus-
derived minimum standards for clinical services delivering
paediatric rheumatology (PRh) care [7]. The SOC were
developed in accordance with national policy at the time
[8, 9] and are endorsed by the Royal College of
Paediatrics and Child Health. Key philosophies underpin-
ning the standards included empowerment of patients
and carers in treatment plans and a holistic approach to
the provision of care. Despite the introduction of the SOC
and an increasing awareness of the negative impact of
delay in access to PRh care on disease outcomes in JIA
[10], a 2013 multi-site UK audit against key SOC demon-
strated considerable variation in service delivery and time
to access specialist care [11]. In addition, the audit
demonstrated a need for consensus agreed and measur-
able JIA-specific quality indicators, reflecting current clin-
ical practice and including both clinician reported and
patient/parent reported outcome measures, to enable
standardization of clinical data collection. The 2013 audit
formed the basis for a successful application to the
Healthcare Quality Improvement Partnership (HQIP) to
support development of the national audit tool for CYP
with JIA. HQIP is an independent organization led by the
Academy of Medical Royal Colleges, The Royal College of
Nursing and National Voices and aims to promote quality
in healthcare, in particular increasing the impact of clinical
audit on healthcare quality improvement.
This paper describes the development of a nationally
agreed tool and dataset for prospective national clinical
audit of JIA. The audit tool will identify key service delivery
measures necessary to benchmark current practice, and
set future standards and targets for improvement; ultim-
ately the aim is to reduce variations in delivery of care and
improve health outcomes for CYP with JIA. To address
the outcomes-based commissioning of National Health
Service (NHS) services, a national clinical audit tool for
JIA must include the UK NHS Specialist Commissioning
for PRh specifications (NHS England Specialised Services
Quality Dashboards) and also patient and carer reported
outcome measures (PROMs) and patient and carer re-
ported experience measures (PREMs).
In parallel to the development of this national audit tool
for JIA, the UK PRh community has derived a
standardized JIA-specific core dataset called Consensus
derived, Accessible (information), Patient-focused, Team-
focused, Universally collected (UK), Relevant to all and
containing Essential data items (CAPTURE-JIA), to facili-
tate comparative clinical studies and research collabor-
ations between providers of care [12]. The ultimate
intention of the BSPAR community is to collect and
embed the nationally agreed audit data items within
CAPTURE-JIA, thereby incorporating indicators of service
delivery, clinical outcomes, carer outcomes and experi-
ence into one dataset to be used in routine clinical prac-
tice to improve patient care.
The aim was to develop a national clinical audit tool for
JIA that would enable evaluation of current clinical prac-
tice against both clinical outcomes and PROM/PREM.
A secondary goal was to set future quality standards
and to ensure these could be regularly assessed by
standardized data collection with CAPTURE-JIA.
Methods
Development of governance structure
To ensure engagement with all relevant stakeholders (clin-
icians, specialist nurses, allied health professionals, aca-
demics and parents/patients), a robust governance
structure comprising three expert groups was established
as follows. A complex and consultative methodology
underpins the development of this JIA audit tool (Fig. 1).
Multidisciplinary scientific steering committee (ScSC)
(n = 14 including representation from all stakeholders)
The committee was responsible for overall operational
management and final decision making. Membership
was open to individuals engaged with development of
BSPAR SOC, CAPTURE-JIA and/or HQIP application.
Multidisciplinary expert group (n = 21, including 11 mem-
bers of the ScSC with representation of all stakeholders)
The group provided expert guidance with powers to rec-
ommend actions. The expert group invited expressions of
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FIG. 1 Methodology flowchart
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interest from all NHS England PRh providers (identified
through the NHS Providers List) and PRh representatives
from Scotland and Wales. A purposeful sample of re-
spondents was invited to participate in the study, with
>80% of all UK sites represented. The sample included
a range of service delivery models and geographic loca-
tions, a spectrum of track records of research from the
National Institute for Health Research (and other research
involvement), PRh national training centres (termed ‘grid
centres’) and other paediatric rheumatology centres
(termed ‘non-grid’).
PROM/PREM development group (n = 17)
This group was responsible for development of novel
PROM and PREM questionnaires suitable for national
audit. The BSPAR National Parents Group was estab-
lished in 2013 to identify and represent the experiences
of families affected by musculoskeletal diagnoses, most
commonly JIA. The PROM/PREM development group
included the BSPAR Parents Group (with representatives
from across England and Scotland), invited consumer rep-
resentatives from the National Institute for Health
Research, Clinical Research Network Children and
Arthritis Research UK Clinical Studies Group and young
people with JIA.
Domains of audit
The ScSC established four domains for the audit, namely
inclusion criteria and patient eligibility, service delivery
quality measures and two aspects of impact, physician
reported outcome measures and PROM/PREMs.
Inclusion criteria and patient eligibility
The ScSC agreed inclusion criteria and eligibility.
Discussion focused on the time window for collection of
audit data, follow-up time per patient and decision to in-
clude only new patients or all patients attending rheuma-
tology outpatients within a given audit time frame. Advice
was taken from the Chair of the British Society for
Rheumatology (BSR) Clinical Affairs Committee, which is
responsible for the National Clinical Audit for Rheumatoid
and Early Inflammatory Arthritis (BSR EIA) [13].
Quality measures
An iterative approach between the ScSC and expert group
was taken. The ScSC derived a preliminary long list of pos-
sible questions addressing key quality measures based on
the BSPAR Standards of Care, the Scottish Paediatric and
Adolescent Rheumatology Network Quality Standards, clin-
ical commissioning requirements in England (NHS England
dashboard for PRh) and additional suggestions from the
wider ScSC. The specific data items required for each qual-
ity measure were listed and duplicate data items were
removed to form a single list.
The feasibility of collecting the proposed list of data
items was discussed with the expert group, highlighting
the need for further prioritization. The ScSC prioritized the
quality measures on the basis of perceived importance,
inclusion in the commissioning dashboard and audibility
(i.e. ease of collection of the necessary data items or over-
lap with CAPTURE-JIA). The expert group were asked to
approve the final list.
To understand the impact of variation in service deliv-
ery, the quality measures will need to be assessed against
the most important clinician reported outcomes and
PROMs/PREMs.
Clinical outcome measures
The ScSC agreed that the primary outcome measure would
be a measure of disease activity and worked in consultation
with the Clinical Studies Group JIA Topic Specific Group to
develop a list of candidate disease activity measures in-
formed by a literature review of disease activity assessment
tools [14] and an audit of disease activity assessment in
clinical practice [12]. All recognized PRh NHS England pro-
viders and representatives from Scotland and Wales were
invited to participate in the audit.
At a facilitated meeting of the expert group, a three-
round nominal group voting exercise was used to achieve
consensus (majority agreement of 570%) on the primary
disease activity measure for inclusion. A consensus def-
inition of 70% was selected to align our work with
consensus definitions favoured by the OMERACT collab-
oration [15] and the Core Outcome Measures in
Effectiveness trials initiative [16]; the consensus cut-off
of 70% has been used in a number of previous paediatric
rheumatology studies [1719]. Following approval by the
ScSC, secondary measures were agreed via an online
consultation process with the expert group.
PROMs/PREMs
Inclusion of PROMs and PREMs was a core requirement
of the project. The PROM/PREM development group led
the development and selection process, using a staged
approach.
Patients and parents attended a facilitated workshop
in which key outcomes and experiences for CYP with
JIA were identified. The open exchange workshop was
moderated by a PRh Consultant (N.W.). Key messages
were brought together during and after the workshop by
one of the consumer members of the BSPAR Parents
Group (S.D.).
Identification of broad themes and sub-themes
Similar items were collapsed into a single item and
grouped into broad themes and sub-themes by a sub-
group of the ScSC. These were approved by the BSPAR
Parents Group.
Comparison with existing validated questionnaires
Any pre-existing validated questionnaires capturing any of
the broad themes or sub-themes prioritized by the patient/
parent group were considered for the audit. Factors con-
sidered included length of questionnaire, ease of scoring
and the time referent period used.
Online prioritization of broad themes and sub-themes
A simple Yes/No online consultation exercise was under-
taken with all members of the PROM/PREM development
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group to determine whether they would prefer one broad
question capturing several aspects of a theme, or one
specific question addressing just one sub-theme.
Questionnaire development workshop
A second facilitated workshop was held to finalize the
development of the PROMs and PREMs. The goals for
this final workshop were to agree the number of patient
outcome and patient experience questions for inclusion,
agree the time reference period for questions (e.g. today,
in the last week, in the last month) and develop wording
for the questions and the format for the answers, ensuring
that the questions were (i) generic (i.e. transferrable to
other paediatric musculoskeletal conditions), (ii) relevant
and valuable to all patients/parents and (iii) suitable for
inclusion in CAPTURE-JIA to facilitate clinical adoption.
Following the meeting, a further online exercise with all
members of the patient/parent group was undertaken for
refinement and final approval of the HQIP audit PROM/
PREM questionnaires.
Testing face validity of the questionnaire
Two additional groups of parents attending one of two JIA
family days in April 2016 (group 1: 20 parents attending a
Scottish Network for Arthritis for Children weekend in
Scotland; group 2: 11 parents attending a JIA family day
in Oxford) were asked to complete the PROM/PREM
questionnaires and an additional brief questionnaire
including questions on completion time, ease of comple-
tion and ease of understanding. A group discussion to
highlight any key issues was facilitated by one of the re-
search team.
A full list of data items and an associated data diction-
ary were prepared.
Results
Membership of each of the three expert groups is pro-
vided online (supplementary Table S1, available at
Rheumatology Online).
Inclusion criteria and eligibility
JIA is an uncommon disease with relatively low numbers
of new patients presenting year-on-year. Therefore, to
ensure capture of sufficient data for meaningful analysis
within a reasonable audit time frame, the ScSC agreed
that all JIA patients (new and follow-up) be included.
Quality measures
The ScSC identified 14 potential quality measures requir-
ing the collection of 40 data items. Overall the expert
group felt that the data required for this would be too ex-
tensive in the absence of an electronic data capture
system. The ScSC therefore agreed to prioritize 11 quality
measures requiring 32 data items, including all those that
map to the commissioning questions (Table 1). The expert
group approved the final list.
Clinical outcome measures
A literature review informed the identification of 19 candi-
date disease activity measures (12 single and 7 composite
measures) by the ScSC in collaboration with the JIA Topic
Specific Group. A subsequent audit of current practice was
completed by 10/14 invited PRh providers (71%), with data
available for 153 children (median age 12 years, range
121 years). Although there was widespread agreement
around important single measures of disease activity
(100% centres intended to collect the core outcome vari-
ables, pain and uveitis), collection and documentation of
these measures was inconsistent and unreliable, ranging
from 87% (active joint count) to 43% (presence/absence
of active uveitis) [12].
This information informed the expert group workshop.
Although some members of the expert group had com-
pleted the audit, the expert group included a wider spec-
trum of centres and non-clinician stakeholders. The expert
group achieved consensus (>70% agreement) on the
three- or four-variable Juvenile Arthritis DAS as the pri-
mary outcome measure [20, 21] and presence/absence
of uveitis (Y or N) as a secondary outcome.
The ScSC approved the choice of outcome measures
but following some discussion, a simple yes/no consult-
ation process with the expert group led to two modifica-
tions; documentation of presence/absence of sacroiliitis in
enthesitis related arthritis and inclusion of the systemic
Juvenile Arthritis DAS composite measure when pub-
lished. The final list of clinical outcome measures is
given in Table 2.
PROMs and PREMs
The initial PROM/PREM development group workshop ini-
tially identified 40 outcomes and 63 experiences. The out-
comes and experiences were subsequently collapsed into
three broad themes with 13 sub-themes for PROMs and
six broad themes with 17 sub-themes for PREMs
(Table 3).
For PROMs, some existing questionnaires were identi-
fied that captured many of the same themes, for example,
Child Health Utility 9D Index (CHU-9D) [22]. However,
these were all considered too long or the scoring
system too complicated for use in an audit. In addition,
the referent time point form most questionnaires was
today only; the group considered this too short a time
frame to provide useful information.
For PREMs, just two pre-existing tools were identified:
The Friends and Family questionnaire [23] and the PREM
developed as part of the BSR EIA [24]. The Friends and
Family questionnaire was considered to be too generic.
The adult inflammatory arthritis PREM has many overlap-
ping domains and could potentially have been adapted;
however, once again the group considered this to be too
long.
A prioritization exercise was sent to the PROM/PREM
development group to identify broad themes and sub-
themes for inclusion and there was an 88% (15 people)
response rate. At the start of the second workshop, those
attending (n = 8) agreed a cut-off of 11/15 (73%) to be the
www.rheumatology.oxfordjournals.org 5
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minimum requirement for inclusion of each theme in
the audit. On initial review, no single broad theme or
sub-theme met these criteria. Discussion continued and
the group achieved consensus (>73%) within the meet-
ing, enabling development of appropriate question and
response options for each theme. Once finalized, the
questions were sent to the wider parent/young person
group (initial 15 respondents), and consensus was once
again achieved.
Given that JIA is a relapsing and remitting condition that
can vary widely over relatively short time periods, a refer-
ent period of 1 month was agreed as sufficient to capture
variability but short enough to minimize recall bias.
Following the workshop, the final set of questions was
sent to all members of the PROM/PREM development
group and minor modifications made based on feedback.
The final PROM and PREM against which the quality
measures will be assessed are shown in Table 2. The
PROM/PREM questionnaires are shown in Table 4.
Feedback from the two additional family groups
(Scotland and Oxford, April 2016) was very similar.
Average time to complete the questionnaire was 3.44
(S.D. 1.49) min for group 1 and 3.45 (S.D. 1.51) min for
group 2; 75% and 100% of groups 1 and 2, respectively,
reported the questionnaire to be ‘easy’ or ‘very easy’ to
complete and 85% and 91%, respectively, were ‘happy’
with the wording used.
Final list of audit data items and associated data
dictionary
The full list of data items (n = 32) plus the PROM/PREM
questionnaire (n = 7) is shown in Table 5. The associated
data dictionary that would need to be collected to quantify
the measures and the outcomes is provided online
(supplementary Table S2, available at Rheumatology Online).
Discussion
This report describes the highly consultative consensus-
based methodology underpinning development of a JIA-
specific national audit tool including identification of key
quality measures for inclusion, and selection of optimal
TABLE 1 Prioritized quality measures
Subject area Proposed question
1. Categorization 1A What is the number of patients in each ILAR sub-group in the audit population?
1B What is the proportion of patients in each ILAR sub-group, relative to the audit population?
2. Access 2 What is the median time for children with suspected JIA from receipt of the referral letter in the
rheumatology department to the date of the first appointment offered in a rheumatology clinic?
(modified PRH03)
(PRH03: children with newly diagnosed JIA should have access to a specialist paediatric rheuma-
tology service within 6weeks of the referral being received by the specialist service)
3. Steroids 3A What is the mean number of days to joint injection on a dedicated paediatric general anaesthesia list
from date of decision to treat, for children of different ILAR sub-types? (PRH04)
(PRH04: Children with JIA who need to have intra-articular steroid injection(s) should wait no longer
than 4weeks for the procedure. Those needing general anaesthesia will have these performed on a
paediatric general anaesthesia list)
3B What percentage of children of different ILAR sub-types is on oral (systemic) steroids at different
times after their first rheumatology clinic visit?
4. DMARDS 4 What is the median time from their first clinic visit to the decision to treat with methotrexate, for
children of different ILAR sub-types?
5. Biologic
therapies
5 What is the median time from their first clinic visit to the decision to treat with their first biologic
therapy?
 for children of different ILAR sub-types
 for different biologic therapies
6 Uveitis 6 What is the median time from the patient’s first clinic visit to the date of their first uveitis screening
with an appropriate paediatric ophthalmic specialist, for patients of different ILAR sub-types?
(modified PRH05)
(PRH05: Children with JIA should have access to uveitis screening within 6weeks of diagnosis)
7. Clinic
organization
7A What proportion of children who started a DMARD or biologic agent were counselled by a paediatric
rheumatology clinical nurse specialist (PRH01)
(PRH01: Children with established rheumatic diseases (and their carers) should be counselled by a
paediatric rheumatology clinical nurse specialist before starting treatment with a DMARD or
Biologic)
7B What proportion of children with JIA is seen in a specialist paediatric rheumatology clinic and what
proportions in other clinic types (modified PRH02)
(PRH02: Children with JIA should have access to a paediatric rheumatology clinic for follow-up
appointments)
8. Research 8 What proportion of eligible patients has been recruited to the BSPAR Cohort Studies (BSPAR
Etanercept and BCRD)?
Where a measure maps to a commissioning item then the commissioning statement is also shown in italics.
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clinician and patient/parent reported outcome tools to
understand the impact of variations in service delivery.
National audit programmes aim to improve disease
outcome for patients. In the UK, the Royal College of
Paediatrics and Child Health supports national audit pro-
grammes in paediatric diabetes, neonatal care and
epilepsy [25]. Such programmes provide an overview
of disease related outcomes and provide potentially
TABLE 2 Measures of clinical outcome, patient reported outcome and patient experience for assessment against quality
measures
Outcome or
experience Proposed measure
(1) Clinical
measures
of outcomes
1A For each ILAR sub-group, what is the median JADAS3 score at different times from the first
clinic appointment?
1B What proportion of patients of different ILAR sub-types have uveitis
1C What proportion of patients with enthesitis related arthritis have sacroiliitis
(1) Patient reported
outcome
measures
2A For each ILAR subtype, what proportion of children (categorized as never, sometimes, often
or most of the time) experience interference with their daily activities due to: fatigue, pain,
poor sleep, medication (side effects)?
2B For each ILAR sub-type, what proportion of children (categorized as never, sometimes, often
or most of the time) have experienced interference with their ability to participate in the
things they like to do (e.g. playing sport, going to the park, playing out, socializing with
friends) due to their condition?
2C For each ILAR sub-type, what proportion of children (categorized as never, sometimes, often
or most of the time) have felt sad/worried or frustrated?
(1) Patient reported
experience
measures
3A What proportion of patients/families felt that their questions and concerns had been an-
swered in a way that they understood (categorized as not at all, a bit, mostly, fully)?
3B What proportion of patients/families understand their treatment plan (categorised as not at
all, a bit, mostly, fully)?
3C What proportion of children/families feel supported in between visits (categorized as not at
all, a bit, mostly, fully)?
3D What proportion of children/families felt that the environment in which they waited was
suitable for those attending the appointment (categorized as not at all, a bit, mostly, fully)?
3E What proportion of patients experienced an unacceptable delay (categorized as no un-
acceptable delay, <15 min, 1530 min, 30 min to 1 h, 12 h, >2 h)?
JADAS3: 3 variable Juvenile Arthritis Disease Activity Score.
TABLE 3 Patient/carer reported outcome and experience measure themes and sub-themes
PROM PREM
Main theme Sub-theme Main theme Sub-theme
Physical well-being Medication and treatment
Physical effects
Pain
Fatigue/sleep
Communication Consistency of advice/care
Relationship with team
Empathy and respect from staff
Information/education Ease of understanding
Education
Financial advice
Social well-being Family impact
Education effects
Lifestyle
Access/coordination of care Journey to diagnosis
Access to all disciplines as required
Access to treatments
Ease of contact with health care professional
Appointment times
Needs/involvement Emotional support
Involving young person in their healthcare
Transition experience
Emotional well-being Uncertainty
Confidence
Frustration
Support
Invisibility
Transition
Environment Hospital/clinic environment
Waiting room environment
Convenience of hospital location
Travel burden
Confidence Confidence/trust in medical team
Confidence/trust in treatment plan
PREM, patient and carer reported experience measure; PROM, patient and carer reported outcome measure.
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powerful benchmarking tools. In diabetes care there is
some evidence that investment in regional networks and
the introduction of a Best Practice Tariff mandating par-
ticipation in audit has resulted in some improvements in
outcome, but this is still relatively limited and also variable
geographically [26]. There are synergies between all
chronic diseases of childhood—fundamentally improving
the quality of care for children is not only important to
control symptoms and alleviate distress, but will also
reduce lifetime risk from complications of the disease.
A further synergy is with inflammatory arthritis in adult-
hood. The first national clinical audit for rheumatoid and
early inflammatory arthritis highlighted geographically
variable gaps between National Institute for Health and
Care Excellence standards and existing care [13]. It is
reasonable to hypothesize that the same gaps are likely
to exist in the provision of paediatric care.
Implementation of a national audit programme for JIA
will require a staged approach. The first step will be an
initial data collection exercise generating benchmarking
data against which robust and validated quality standards
can be set. This will facilitate effective quality assessment
for NHS England commissioning of specialized services.
The second data collection phase will assess how well the
standards are being met in terms of the quality, safety,
outcome and experience of care for CYP with JIA.
Future participation of all PRh NHS Providers in a na-
tional clinical audit process evaluating the care of CYP
with JIA will capture a more complete impression of
what is happening at local (Trust), regional and national
levels. The completion of the audit tool could in itself be
considered a quality measure for the delivery of care in
JIA. Collecting audit data in itself (challenging though this
is) is simply not enough—the data must be utilized to ac-
tually deliver the change required to drive quality improve-
ments and this requires concerted effort and commitment
from all stakeholders’ services and access to fit-for-
purpose IT systems.
Describing and understanding current clinical practice
through national clinical audit will enable the development
of robust and meaningful quality standards that will be
used to drive improvements in clinical care and outcomes
for JIA. Important national audit questions and quality
measures may change over time. In particular, the current
TABLE 5 Audit data items
Section Data item
General (dates) 1.1 NHS number of patient (Scotland: CHI number; Northern Ireland: H and C number)
1.2 Date of attendance
1.3 Date of referral letter arriving in rheumatology department
1.4 Date of first appointment offered in a rheumatology clinic
1.5 Date of first appointment in a rheumatology clinic
1.6 Date of first eye screen
Demographics 2.1 Date of birth
Diagnosis 3.1 ILAR sub-type
Medication 4.1 Medication name
4.2 Route
4.3 Did the decision to treat with steroid injection specify a dedicated paediatric general
anaesthesia list?
4.4 Date of decision to treat or change treatment
4.5 Date treatment started/date of single treatment
4.6 Date patient was counselled before starting a DMARD
4.6 Date patient was counselled before starting a biologic agent
4.7 Date medication stopped or changed
4.8 Reason for stopping or changing medication
Clinic organization 5.1 Clinic organization
Research 6.1 Is the patient eligible for the recruitment to the BSPAR Etanercept Cohort Study?
6.2 Has the patient been recruited to the BSPAR Etanercept Cohort Study?
6.3 Is the patient eligible for recruitment to the BCRD study?
6.4 Has the patient been recruited to the BCRD study?
(Core) Outcome variables 7.1.A Active joint assessment
7.1.B Swollen joint assessment
7.1.C Tender joint assessment
7.2 Physician global assessment
7.3 Patient/parent global assessment of overall well-being
7.4 CHAQ/HAQ
7.5.A ESR
7.5.B Plasma viscosity
7.6 Date COVs assessed
7.7 Uveitis status at most recent eye examination
BCRD: Biologics for Children with Rheumatic Diseases; BSPAR: British Society for Paediatric and Adolescent Rheumatology.
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audit tool does not include an assessment of damage.
Clinical and radiological evidence of damage occurs rela-
tively late in JIA and damage assessment tools are not
currently used routinely in clinical practice. Although a
valid and meaningful assessment of damage could not
be included in the audit tool at this time, damage may
merit inclusion in future iterations, as damage assessment
tools evolve further.
The active participation of the wider PRh clinical and
research communities across the UK is an important
strength of this study. It demonstrates the widespread
support for projects informing best practice, the need
for greater collaboration between centres, and support
for a consensus process to agree and define a feasible
dataset (i.e. set of data items to be collected) to encom-
pass the needs of patients and families, clinical teams,
research teams, service providers and commissioners.
Although we acknowledge that our primary aim of assess-
ing all patients with new onset JIA may be aspirational, the
active participation of the wider PRh community in this
and other national projects suggests that identification
of all new patients could be a realistic expectation.
Patient experience and outcomes are key quality indi-
cators but few condition-specific paediatric PREMs are
available. A further strength of the study is the methodo-
logically sound development of novel PROM/PREM tools
specific to JIA and developed in consultation with the
BSPAR Parents Group.
A major challenge for the PROM/PREM development
group was achieving agreement on which broad themes
and sub-themes to include. While agreement was
achieved, a number of important sub-themes have been
excluded. Future development of an electronic data col-
lection tool may enable inclusion of further data items.
The PROM/PREM tools require further validation and pilot-
ing prior to incorporation into standard clinical practice.
A consensus agreed core dataset for JIA (CAPTURE-JIA),
which incorporates the audit data items, has been developed
and is currently being piloted. Once finalized, embedding the
collection of CAPTURE-JIA data items into routine clinical
care would facilitate a national audit programme.
The longer-term goal is development of an electronic
data collection tool with routine integration of data collec-
tion into electronic patient records. Improved documenta-
tion (and auditing) of service delivery at local (trust),
regional (clinical networks) and national level against
these important clinical and consumer reported outcomes
will likely identify potential areas for healthcare quality im-
provement, key to improving clinical outcomes for this
vulnerable group of patients.
Implementation of the proposed national audit tool
should facilitate investigation of variability between ser-
vices and across networks, identify current levels of care
and drive a long-term quality improvement programme for
children and young people with JIA. Healthcare providers
designated as providing paediatric rheumatology services
should be held accountable to address inadequacies in
care and recommendations when demonstrated using
the validated audit tool.
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